Zofenopril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Zofenopril is an ACE inhibitor indicated in the treatment of hypertension.

Generic Name
Zofenopril
DrugBank Accession Number
DB13166
Background

Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 429.55
Monoisotopic: 429.106850573
Chemical Formula
C22H23NO4S2
Synonyms
  • Zofenil
  • Zofénopril
  • Zofenopril
  • Zofenoprilum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute myocardial infarction (ami)••••••••••••
Treatment ofHigh blood pressure (hypertension)••••••••••••
Used in combination to treatMild to moderate hypertensionCombination Product in combination with: Hydrochlorothiazide (DB00999)••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideAbaloparatide may increase the hypotensive activities of Zofenopril.
AcebutololAcebutolol may increase the hypotensive activities of Zofenopril.
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Zofenopril.
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Zofenopril.
Acetylsalicylic acidThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Acetylsalicylic acid.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Zofenopril calcium88ZQ329PU281938-43-4NSYUKKYYVFVMST-LETVYOFWSA-L
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BIFRIL PLUSZofenopril (30 MG) + Hydrochlorothiazide (12.5 MG)Tablet, film coatedOralบริษัท เอ. เมนารินี (ประเทศไทย) จำกัด2017-05-09Not applicableThailand flag
BIFRIL PLUS 30/12.5 MG FILM TABLET, 28 ADETZofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg)Tablet, film coatedOralULAGAYLAR İLAÇ SAN. VE TİC. A.Ş.2007-11-262022-06-30Turkey flag
BIFRIL PLUS 30/12.5 MG FILM TABLET, 84 ADETZofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg)Tablet, film coatedOralULAGAYLAR İLAÇ SAN. VE TİC. A.Ş.2007-11-262022-06-30Turkey flag
BIFRIZIDEZofenopril calcium (30 MG) + Hydrochlorothiazide (12.5 MG)Tablet, coatedOralIstituto Luso Farmaco D'italia S.P.A.2014-07-08Not applicableItaly flag
BIFRIZIDEZofenopril calcium (30 MG) + Hydrochlorothiazide (12.5 MG)Tablet, coatedOralIstituto Luso Farmaco D'italia S.P.A.2014-07-08Not applicableItaly flag

Categories

ATC Codes
C09BA15 — Zofenopril and diureticsC09AA15 — Zofenopril
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Thiobenzoic acids and derivatives / Benzoic acids and derivatives / Thiophenol ethers / Pyrrolidine carboxylic acids / Benzoyl derivatives / N-acylpyrrolidines / Alkylarylthioethers / Tertiary carboxylic acid amides / Thioesters
show 10 more
Substituents
Alkylarylthioether / Aromatic heteromonocyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzoic acid or derivatives / Benzoyl / Carbonyl group / Carbothioic s-ester / Carboxamide group
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
thioester, aryl sulfide, N-acyl-L-amino acid, L-proline derivative (CHEBI:78539)
Affected organisms
Not Available

Chemical Identifiers

UNII
290ZY759PI
CAS number
81872-10-8
InChI Key
IAIDUHCBNLFXEF-MNEFBYGVSA-N
InChI
InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1
IUPAC Name
(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylic acid
SMILES
C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1

References

General References
  1. Nilsson P: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:25-30. [Article]
  2. Mallion JM: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:13-8. [Article]
  3. AIFA Product Information: Bifril (zofenopril calcium) film-coated tablets [Link]
KEGG Drug
D08688
PubChem Compound
92400
PubChem Substance
347829273
ChemSpider
83422
BindingDB
50084629
RxNav
39990
ChEBI
78539
ChEMBL
CHEMBL331378
ZINC
ZINC000003775162
Wikipedia
Zofenopril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentHypertension3
4RecruitingTreatmentCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral15.000 mg
Tablet, coatedOral15 mg
TabletOral30 mg
Tablet, coatedOral30 mg
Tablet, film coatedOral7.5 mg
Tablet, film coatedOral
Tablet, film coatedOral30 mg
TabletOral
Tablet, coatedOral
Tablet, film coatedOral
Tablet, film coatedOral15 MG
Tablet, film coatedOral60 MG
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00311 mg/mLALOGPS
logP3.64ALOGPS
logP4.31Chemaxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.5Chemaxon
pKa (Strongest Basic)-1.3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area74.68 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity116.82 m3·mol-1Chemaxon
Polarizability46.1 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-053r-0465900000-2a77f2eb6d7d6a8021b1
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-2623900000-b7d81fdd80cf9665b0f5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0930100000-210777289f6c9dd1e452
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9510100000-9cc00c2d8b594dd15f47
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0bt9-2911000000-c149ce26e96b5fb4ac72
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-2900000000-5a0f4fd2ac8202f18c65
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-203.1022559
predicted
DarkChem Lite v0.1.0
[M-H]-190.83356
predicted
DeepCCS 1.0 (2019)
[M+H]+204.7551559
predicted
DarkChem Lite v0.1.0
[M+H]+193.69228
predicted
DeepCCS 1.0 (2019)
[M+Na]+202.8713559
predicted
DarkChem Lite v0.1.0
[M+Na]+201.00893
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Ambrosioni E: Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7(1):17-24. [Article]

Drug created at February 11, 2017 15:59 / Updated at June 05, 2021 09:12